Zicix (OTCMKTS:ZICX – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.
Risk & Volatility
Zicix has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.1, indicating that its stock price is 10% more volatile than the S&P 500.
Earnings & Valuation
This table compares Zicix and Viridian Therapeutics”s revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Zicix | N/A | N/A | N/A | N/A | N/A |
Viridian Therapeutics | $302,000.00 | 5,736.39 | -$237.73 million | ($4.31) | -5.07 |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Zicix and Viridian Therapeutics, as reported by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Zicix | 0 | 0 | 0 | 0 | 0.00 |
Viridian Therapeutics | 0 | 2 | 9 | 0 | 2.82 |
Viridian Therapeutics has a consensus price target of $36.33, suggesting a potential upside of 66.13%. Given Viridian Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Zicix.
Profitability
This table compares Zicix and Viridian Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Zicix | N/A | N/A | N/A |
Viridian Therapeutics | -85,127.16% | -70.12% | -41.49% |
Summary
Viridian Therapeutics beats Zicix on 5 of the 8 factors compared between the two stocks.
About Zicix
Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.
About Viridian Therapeutics
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Zicix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zicix and related companies with MarketBeat.com's FREE daily email newsletter.